Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 572 across all filing types
Latest filing 2024-05-10 Share Issue/Capital Cha…
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
Softox Solutions AS: New share capital
Share Issue/Capital Change Classification · 98% confidence The document is a short announcement (1780 characters) titled "Softox Solutions AS: New share capital". It explicitly states that the new share capital has been registered following a 'Subsequent Offering' and details the resulting number of shares and par value. This directly relates to a change in the company's capital structure, specifically the issuance of new shares resulting from a financing activity. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full report, an earnings release, or a dividend notice.
2024-05-10 English
SoftOx Solutions AS: Final result of the Subsequent Offering and allocation of Offer Shares
Share Issue/Capital Change Classification · 99% confidence The document announces the 'Final result of the Subsequent Offering and allocation of Offer Shares' for SoftOx Solutions AS. It details the subscription price, the number of shares allocated, the gross proceeds (NOK 2.7 million), and mentions that notifications will be sent out separately. This content directly relates to a capital raising or financing activity, specifically the finalization of a share offering. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory announcement (RNS), as it concerns a specific financing event.
2024-04-30 English
Softox Solutions AS – Close of Subscription Period today
Capital/Financing Update Classification · 98% confidence The document announces the closing of a subscription period for a subsequent offering of new shares. This action directly relates to fundraising, capital structure changes, and the issuance of new securities. This aligns best with the 'Capital/Financing Update' category (CAP). Although it involves shares, it is about the offering/subscription process rather than a general share issue announcement (SHA) or a buyback (POS). The document is short and serves as an announcement regarding a financing event.
2024-04-29 English
SOFTX: COMMISSIONED RESEARCH REPORT - Promising antimicrobial technology - further advancement dependent on sufficient funding
Investor Presentation Classification · 98% confidence The document is a detailed research report published by SpareBank 1 Markets on SoftOx Solutions, dated 22/04/2024. It contains investment highlights, valuation analysis, a summary of the investment case, details on technology, and projections for future funding rounds (NOK50m for Phase 2, NOK130m for Phase 3). The structure, content (Investment highlights, Valuation thoughts, Summary), and the source (a financial institution's research division) strongly indicate this is an Investor Presentation or a detailed research report intended for investors. It is not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a simple announcement of a report (RPA). Given the depth of analysis and presentation format, 'Investor Presentation' (IP) is the most appropriate classification.
2024-04-23 English
SOFTX: COMMISSIONED RESEARCH REPORT - Promising antimicrobial technology - further advancement dependent on sufficient funding
Investor Presentation Classification · 98% confidence The document is explicitly titled 'SOFTX: COMMISSIONED RESEARCH REPORT' and details an analysis, valuation thoughts, and conclusions regarding a specific company's technology and funding needs, commissioned by Sparebanken 1 Markets. This content structure—an external analyst's deep dive into a company's prospects, technology, and valuation—is characteristic of an Investor Presentation (IP) or a detailed research report provided to investors. Since 'Investor Presentation (IP)' covers detailed presentations focusing on financials, strategy, and market position, and this document serves that function (even if commissioned research), it fits best under IP. It is not a regulatory filing (like 10-K, ER, or IR), nor is it a short announcement (RPA/RNS).
2024-04-23 English
SoftOx Solutions AS: Presentation deck and link for todays presentation
Investor Presentation Classification · 99% confidence The document is titled 'Presentation of "New SoftOx" 18 April 2024' and features slides detailing company restructuring, investment highlights, scientific background (HOCl), project plans (VAP Phase 2), and speaker introductions. This format, content focus on strategy, financials, and future plans presented to investors, strongly indicates an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT). The document length is substantial (over 30k characters), confirming it is the presentation material itself, not just an announcement of publication (RPA).
2024-04-18 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.